Press Kit
Salvat at a glance
If you are a media professional and wish to receive more information, please send us an email at media@svt.com.
Salvat’s News and Press kit
Media
Salvat at a glance
Press Kit
What are we doing right now
News
Media
Salvat’s News and Press kit
Media
Salvat at a glance
Press Kit
What are we doing right now
News
Media
Salvat at a glance
If you are a media professional and wish to receive more information, please send us an email at media@svt.com.
English Version PDF
What are we doing right now
| Cookie | Duration | Description |
|---|---|---|
| _ga | 2 years | Google Analytics |
| _gat_gtag_UA_112188601_1 | 2 years | Google Analytics |
| _gid | 2 years | Google Analytics |
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| ip2location_redirection_first_visit | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
| PHPSESSID | session | Identificador de sesión PHP / PHP session id |
| prescriptionModalAccepted | session | Identificador de sesión PHP / PHP session id |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
| wpml_browser_redirect_test | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
| _icl_visitor_lang_js | session | Mostrar las páginas de la web en el idioma seleccionado / Browse this website pages in the selected language |
Salvat Laboratory submits application to the U.S. FDA for approval of Clotrimazole, a pioneering drug for the treatment of otomycosis
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezThe new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa. Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international […]
Salvat Laboratory obtains the qualification “Excellent” in the PROFARMA program
/in Salvat Spain /by Carme LopezSalvat is one of the top-rated pharmaceutical companies that has achieved the best rating in the PROFARMA program, among the 49 evaluated by the Ministry of Industry, Trade and Tourism. The PROFARMA Plan seeks to increase the competitiveness of the industry through the modernization of the sector and the enhancement of activities that provide greater […]
Salvat Laboratories announces submission of New Drug Application to the U.S. FDA for Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezSalvat Laboratories, the international company which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients. […]
Salvat, pioneer in using cell-therapy for the treatment of non-consolidated bone fractures (BONECURE project)
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezIt is an innovative project based on pre-differentiated mesenchymal stem cells designed to treat patients with bone consolidation problems post-fracture (atrophic pseudoarthrosis). A Phase II clinical trial has been completed, with very promising results in terms of efficacy and safety, in patients with pseudoarthrosis of long bones. Salvat has invested more than 10 million Euros […]
Salvat plans to launch the first global ocular corticosteroid with nanoemulsion in 2023 for the inflammation and pain after ocular surgery
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezPhase III clinical trials conducted in US confirm that clobetasol is effective and safe in the treatment of inflammation and pain after cataract surgery. The pharmaceutical company has begun the process with health authorities to market the new corticosteroid worldwide by the middle of next year. The company has patented a pioneering technology, IMPACT-SVT®, which […]